Global Health Watch 1 in one file
Global Health Watch 1 in one file Global Health Watch 1 in one file
Health care systems | B1 ing services, highlighting the ephemeral nature of gains secured by vertical initiatives. Today, selective approaches are a prominent feature of the international health policy landscape. Despite rhetoric about the need to improve coordination between different disease-based programmes and to complement vertical initiatives with a health systems development agenda, the multitude of singlefocus or single-disease initiatives is reminiscent of the heyday of vertical programmes in the 1980s. At the country level, recipient governments are expected to dance to the tune of an international agenda rather than developing targets, policies and plans based on their own circumstances. Health care responses to high morbidity and mortality reflect a biomedical and ‘technological’ bias (vaccines, medicines or new technologies such as insecticide treated bednets) while a coherent and financially-backed agenda for the long-term and sustainable development of equitable health systems remains absent. The Millennium Development Goals are also placing health services under pressure to achieve the MDG targets through selective interventions. It has been calculated that making 15 preventive interventions and eight treatment interventions universally available in 42 counties would achieve the MDG child mortality target (Jones et al. 2003). The pressure on governments to apply for and disburse quickly resources from new financing instruments, such as the Global Fund to fight AIDS, TB and Malaria (GFATM), so as to show the positive impact of such bodies, could also undermine cohesive health systems development (Box B1.6). According to one group of child health experts, although many of the current disease-specific initiatives relate at least indirectly to child survival, and in this sense have expanded the resources available to child health, ‘the result is a set of fragmented delivery systems, rather than a coordinated effort to meet the needs of children and families’ (Bellagio Study Group on Child Survival 2003). They note that ‘in today’s environment of disease-specific initiatives, cross-disease planning, implementation, and monitoring are hard to establish and maintain’. Paradoxically, the threat of narrow, disease-based programmes disrupting health care systems is most acute where such systems are already fragile and under-resourced (Victora et al. 2003). Many of the selective health care initiatives now operate as Global Public Private Initiatives (Box B1.7), introducing a much higher level of involvement from the commercial/private sector. This brings in private financing and private sector ‘know-how’, but at the same time provides the commercial sector with further public subsidies, and the opportunity to capture a share of the resulting market for their products. 72
Box B1.6 The pitfalls of expanding anti-retroviral treatment in developing countries On the back of inspiring civil society campaigns to reduce the price of anti-retroviral treatment (ART), millions of dollars are now being directed at expanding access to these medicines. However, there are several pitfalls in this largesse that are particularly relevant to countries with underresourced, disorganized and inequitable health care systems (McCoy et al 2005). One is that access to ART could be expanded at the expense of other vital health care services, or could divert resources away from the prevention of HIV transmission. A focus on ART could also ‘over-medicalize’ the response to HIV/AIDS, and turn attention away from the political, social and economic determinants of the epidemic. A second pitfall is that ART programmes may take inappropriate ‘shortcuts’ to achieve ambitious coverage targets and compromise on the quality and long-term outcome of care. Insufficient community and patient preparation, erratic and unsustainable drug supplies, and inadequate training and support of health care providers could result in low levels of treatment adherence, tending to an increased threat of drug resistance. A third pitfall arising out of the pressure to achieve quick results is the use of non-government supply and delivery systems for ART because of their ability to set projects up quickly. Apart from the additional burden of coordinating and monitoring multiple non-government treatment services, this approach can weaken the capacity of the public sector health care system still further by draining skilled personnel into the better-paid independent sector. Finally, ambitious ART coverage targets may lead to a preferential targeting of easier-to-reach, higher-income groups, typically those living in urban areas, and thereby widening existing health care inequities. A treatment– focused approach that inadequately addresses the basic needs of households, such as food security and access to water, will limit the capacity of the poor to benefit from ART. Narrow, ‘selective’ or disease-based programmes or initiatives are not inherently bad, nor are they always influenced by undue commercial considerations. For some health interventions, for example those related to the control Approaches to health care 73
- Page 40 and 41: Health and globalization | A1 and p
- Page 42 and 43: Health and globalization | A1 econo
- Page 44 and 45: Health and globalization | A1 Box A
- Page 46 and 47: Health and globalization | A1 half
- Page 48 and 49: Health and globalization | A1 appro
- Page 50 and 51: table a1 Key health concerns with W
- Page 52 and 53: Health and globalization | A1 Healt
- Page 54 and 55: Health and globalization | A1 merci
- Page 56 and 57: Health and globalization | A1 thems
- Page 58 and 59: Health and globalization | A1 Even
- Page 60 and 61: Health and globalization | A1 • A
- Page 62 and 63: Health and globalization | A1 non-v
- Page 64 and 65: Health and globalization | A1 27-28
- Page 66 and 67: Health and globalization | A1 Jenki
- Page 68 and 69: Health and globalization | A1 Satte
- Page 70 and 71: Health and globalization | A1 WHO (
- Page 72 and 73: and regulatory authorities mandated
- Page 74 and 75: Health care systems | B1 4) selecti
- Page 76 and 77: Health care systems | B1 • And si
- Page 78 and 79: Health care systems | B1 • declin
- Page 80 and 81: Health care systems | B1 user charg
- Page 82 and 83: Health care systems | B1 focus on t
- Page 84 and 85: Health care systems | B1 for health
- Page 86 and 87: Health care systems | B1 their cont
- Page 88 and 89: Health care systems | B1 health car
- Page 92 and 93: Health care systems | B1 Box B1.7 G
- Page 94 and 95: Health care systems | B1 many of th
- Page 96 and 97: Health care systems | B1 the lack o
- Page 98 and 99: Macro-economic factors Impoverished
- Page 100 and 101: Health care systems | B1 HALE 2000
- Page 102 and 103: Health care systems | B1 But improv
- Page 104 and 105: Health care systems | B1 high-incom
- Page 106 and 107: Health care systems | B1 Structural
- Page 108 and 109: Health care systems | B1 the high t
- Page 110 and 111: Health care systems | B1 and histor
- Page 112 and 113: Health care systems | B1 norms (Loe
- Page 114 and 115: Health care systems | B1 Foster M,
- Page 116 and 117: Health care systems | B1 Toole M et
- Page 118 and 119: B2 | Medicines Introduction Essenti
- Page 120 and 121: Health care systems | B2 of new med
- Page 122 and 123: Health care systems | B2 chapter re
- Page 124 and 125: Health care systems | B2 the fourth
- Page 126 and 127: Health care systems | B2 agenda thr
- Page 128 and 129: Health care systems | B2 nonetheles
- Page 130 and 131: Health care systems | B2 decision o
- Page 132 and 133: Health care systems | B2 for the an
- Page 134 and 135: Health care systems | B2 expenditur
- Page 136 and 137: Health care systems | B2 Medawar C
- Page 138 and 139: Health care systems | B3 between he
<strong>Health</strong> care systems | B1<br />
<strong>in</strong>g services, highlight<strong>in</strong>g the ephemeral nature of ga<strong>in</strong>s secured by vertical<br />
<strong>in</strong>itiatives.<br />
Today, selective approaches are a prom<strong>in</strong>ent feature of the <strong>in</strong>ternational<br />
health policy landscape. Despite rhetoric about the need to improve coord<strong>in</strong>ation<br />
between different disease-based programmes and to complement vertical<br />
<strong>in</strong>itiatives with a health systems development agenda, the multitude of s<strong>in</strong>glefocus<br />
or s<strong>in</strong>gle-disease <strong>in</strong>itiatives is rem<strong>in</strong>iscent of the heyday of vertical programmes<br />
<strong>in</strong> the 1980s. At the country level, recipient governments are expected<br />
to dance to the tune of an <strong>in</strong>ternational agenda rather than develop<strong>in</strong>g targets,<br />
policies and plans based on their own circumstances. <strong>Health</strong> care responses<br />
to high morbidity and mortality reflect a biomedical and ‘technological’ bias<br />
(vacc<strong>in</strong>es, medic<strong>in</strong>es or new technologies such as <strong>in</strong>secticide treated bednets)<br />
while a coherent and f<strong>in</strong>ancially-backed agenda for the long-term and susta<strong>in</strong>able<br />
development of equitable health systems rema<strong>in</strong>s absent.<br />
The Millennium Development Goals are also plac<strong>in</strong>g health services under<br />
pressure to achieve the MDG targets through selective <strong>in</strong>terventions. It has<br />
been calculated that mak<strong>in</strong>g 15 preventive <strong>in</strong>terventions and eight treatment<br />
<strong>in</strong>terventions universally available <strong>in</strong> 42 counties would achieve the MDG child<br />
mortality target (J<strong>one</strong>s et al. 2003). The pressure on governments to apply for<br />
and disburse quickly resources from new f<strong>in</strong>anc<strong>in</strong>g <strong>in</strong>struments, such as the<br />
<strong>Global</strong> Fund to fight AIDS, TB and Malaria (GFATM), so as to show the positive<br />
impact of such bodies, could also underm<strong>in</strong>e cohesive health systems development<br />
(Box B1.6).<br />
Accord<strong>in</strong>g to <strong>one</strong> group of child health experts, although many of the current<br />
disease-specific <strong>in</strong>itiatives relate at least <strong>in</strong>directly to child survival, and <strong>in</strong><br />
this sense have expanded the resources available to child health, ‘the result is<br />
a set of fragmented delivery systems, rather than a coord<strong>in</strong>ated effort to meet<br />
the needs of children and families’ (Bellagio Study Group on Child Survival<br />
2003). They note that ‘<strong>in</strong> today’s environment of disease-specific <strong>in</strong>itiatives,<br />
cross-disease plann<strong>in</strong>g, implementation, and monitor<strong>in</strong>g are hard to establish<br />
and ma<strong>in</strong>ta<strong>in</strong>’. Paradoxically, the threat of narrow, disease-based programmes<br />
disrupt<strong>in</strong>g health care systems is most acute where such systems are already<br />
fragile and under-resourced (Victora et al. 2003).<br />
Many of the selective health care <strong>in</strong>itiatives now operate as <strong>Global</strong> Public<br />
Private Initiatives (Box B1.7), <strong>in</strong>troduc<strong>in</strong>g a much higher level of <strong>in</strong>volvement<br />
from the commercial/private sector. This br<strong>in</strong>gs <strong>in</strong> private f<strong>in</strong>anc<strong>in</strong>g and private<br />
sector ‘know-how’, but at the same time provides the commercial sector<br />
with further public subsidies, and the opportunity to capture a share of the<br />
result<strong>in</strong>g market for their products.<br />
72